Ten years after the introduction of the Senegalese Antiretroviral Drug Access Initiative in 1998, we conducted a retrospective study of the epidemiological and clinical profiles and outcome of HIV-infected patients hospitalized in the Infectious Diseases Clinic of Fann Teaching Hospital in Dakar between 2007 and 2008. During these 2 years, 527 HIV-positive patients were included. The average age of the patients was 41 ± 10 years, and the sex-ratio (F/M) was 1.1; 56% of patients were married. The average interval before admission was 40 ± 57 days. Fever (83%), loss of weight (83%) and cough (54%) were the principal symptoms. Tuberculosis (40.9%) and gastrointestinal candidiasis (38.9%) were the commonest opportunistic infections. Most patients were diagnosed at the AIDS stage (88%) and the CD4+ T lymphocyte count was ≤ 200/mm3 in 86% of cases. Hospital fatality was 44% (231/527). Tuberculosis (36%), bacterial pneumonia (18%) and encephalitis (12%) were the most frequent causes of death. Despite the availability of and free access to antiretroviral drugs in Senegal, the mortality associated with HIV infection remains very high due to late diagnosis. The population must be educated to boost early screening and care.

Context: Senegal is among the most endemic countries for viral hepatitis B with 11% of chronic HBV carriers. Students in the health sector are among those most at risk. The objectives of this study were to determine the Knowledge, Attitudes and Practices (KAP) of students at a private university in Dakar regarding viral hepatitis B and to identify associated factors. Methodology: A cross-sectional, descriptive, and analytical study has been conducted among students of the St Christopher Iba Mar Diop School from April 1 to 30, 2019. The questionnaire was self-administered. Chi 2 testing and logistic regression were used to identify factors associated with the level of knowledge, as well as attitudes and practices regarding viral hepatitis B. The data was analyzed using SPSS version 22 software. Results: In total, we interviewed 317 students, which corresponds to a participation rate of 60.5%. The main sources of information were predominately training (85.9%) and the media (68.2%). Jaundice (85.9%), hepatomegaly (79.2%) and fever (78.5%) were the main clinical signs known to students. Blood and sexual transmission routes were cited by more than 80% of the respondents. However, 19.4% of students reported that hepatitis B could be transmitted by the fecal-oral route. People with multiple sexual partners (77.5%) and health workers (76.4%) were the most frequently cited at-risk groups. Incarceration as a risk factor was known by only 38.7% of respondents.

No abstract

IntroductionLe VIH-2, endémique en Afrique de l'Ouest, est naturellement résistant aux inhibiteurs non nucléosidiques de la rétro transcriptase (INNRTI), ce qui rend difficile la prise en charge dans les pays en développement. L’objectif ici était de déterminer la prévalence de l'échec virologique au 12éme et 24éme mois (M12 et M24) de traitement antirétroviral de première ligne chez les patients infectés par le VIH-2 et d'en décrire les résistances génotypiques associées.MéthodesIl s'agit d'une étude descriptive longitudinale et prospective, durant la période de novembre 2005 à juin 2017. L'échec virologique a été défini comme toute charge virale supérieure à 50 copies/ml après 6 mois de traitement ARV à deux reprises. La recherche de mutations de résistance a été réalisée dans les régions codantes de la protéase et de la transcriptase inverse.RésultatsAu total 110 patients ont été colligés, d'âge médian de 46 ans (Extrêmes 18-67) avec un ratio F/H de 2,54. À l'inclusion, la charge virale était détectable dans 44% des cas avec une médiane de 935cp/ml (Extrêmes 17-144038). Le schéma antirétroviral associait 2 INTI à 1IP dans 94% des cas. La durée médiane de suivi était estimée à 1200 jours (Extrêmes 1-3840). 94 puis 76 patients ont respectivement complété leur bilan à M12 et M24. Au suivi M24, 39 patients étaient en échec virologique soit une prévalence de 39% estimée à 33% à M12 et 11% à M24. 45% des patients avaient des résistances aux inhibiteurs nucléosidiques de la transcriptase inverse (INTI), 41% des résistances aux IP et 30% des multi résistances aux INTI et IP.ConclusionIl est impératif de rendre accessible les nouvelles classes thérapeutiques pour le traitement de sauvetage des patients infectés par le VIH-2 dans les pays à ressources limitées.

No abstract